SCHEMBL4496183

SCHEMBL4496183

COc1ccc2cc(C(=O)O)c(NCc3cccc(Br)c3)nc2c1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.46
HPGD P15428 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
HPGDS O60760 1/20 0.44
GPBAR1 Q8TDU6 1/20 0.44
APP P05067 2/20 0.43
EGFR P00533 3/20 0.43
APEX1 P27695 1/20 0.43
RAB9A P51151 2/20 0.42
AURKA O14965 2/20 0.42
RPS6KB1 P23443 2/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
SLC26A6 Q9BXS9 1/20 0.41
POLB P06746 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
NPC1 O15118 1/20 0.41
HIF1A Q16665 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4500058 0.91 SMN1; SMN2 (0.53) LMNASMN1; SMN2HPGDSAPPEGFR
SCHEMBL4489260 0.89 HPGDS (0.55) LMNAHPGDSMN1; SMN2HPGDSAPP
SCHEMBL4501469 0.88 APEX1 (0.49) LMNAHPGDSMN1; SMN2HPGDSAPP
SCHEMBL4484547 0.88 APP (0.48) HPGDSMN1; SMN2HPGDSAPPEGFR
SCHEMBL4487073 0.86 KDM4E (0.53) HPGDHPGDSAPPEGFRRAB9A
SCHEMBL4493680 0.85 MITF (0.56) APPAURKARPS6KB1MEN1KMT2A
SCHEMBL4489700 0.84 HIF1A (0.58) LMNASMN1; SMN2RAB9AAURKARPS6KB1
SCHEMBL4482214 0.84 AURKA (0.49) SMN1; SMN2APPAURKARPS6KB1HIF1A
SCHEMBL4477510 0.83 KDM4E (0.47) HPGDSMN1; SMN2HPGDSGPBAR1EGFR
SCHEMBL4487160 0.83 HPGDS (0.47) HPGDSMN1; SMN2HPGDSEGFRRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7482455-B2 Chemical compounds SMITHKLINE BEECHAM CORPORATION (US) 2009-01-27 US claimed
EP-1556379-A4 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2007-06-13 EP claimed
US-20060106058-A1 Chemical compounds BURGESS JOELLE L 2006-05-18 US claimed
EP-1556379-A2 CHEMICAL COMPOUNDS SmithKline Beecham Corporation (US) 2005-07-27 EP claimed
WO-2004034985-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2004-04-29 WO claimed
US-7482455-B2 Chemical compounds SMITHKLINE BEECHAM CORPORATION (US) 2009-01-27 US disclosed
EP-1556379-A4 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2007-06-13 EP disclosed
US-20060106058-A1 Chemical compounds BURGESS JOELLE L 2006-05-18 US disclosed
EP-1556379-A2 CHEMICAL COMPOUNDS SmithKline Beecham Corporation (US) 2005-07-27 EP disclosed
WO-2004034985-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2004-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060106058-A1 Chemical compounds YARS1, DAPK3, NEK3 LMNA 2030/4885HPGD 3067/4885SMN1; SMN2 4328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.